Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NMDA and Cognitive Remediation in Schizophrenia

NCT01474395 is registered in ClinicalTrials.gov with Nathan Kline Institute for Psychiatric Research as lead sponsor.

NCT NCT01474395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01474395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NMDA and Cognitive Remediation in Schizophrenia
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2012
Completion date
June 30, 2013
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia